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Abstract 
Synovial sarcomas are soft-tissue malignan-
cies with a poor prognosis and propensity for
distant  metastases.  Although  originally
believed  to  arise  from  the  synovium,  these
tumors have been found to occur anywhere in
the body. We report a rare case of synovial sar-
coma arising from the median nerve. To our
knowledge, this is the twelfth reported case of
intraneural  synovial  sarcoma,  and  only  the
fourth arising from the median nerve. Because
the diagnosis may not be apparent until after
pathological examination of the surgical speci  -
men, synovial sarcoma should be kept in mind
when  dealing  with  what  may  seem  like  a
benign nerve tumor.
Introduction
Synovial  sarcomas  are  aggressive  soft-tis-
sue malignancies with a propensity for distant
metastases,  and  can  occur  anywhere  in  the
body.
1,2 They account for approximately 5-10%
of soft tissue sarcomas, with about 800 cases
per year in the United States. Overall, progno-
sis is poor, with only a 50-60% five-year sur-
vival  rate  despite  radical  surgical  resection,
local  irradiation,  and  a  fairly  high  response
rate  to  chemotherapy.
3 Although  they  have
been reported in patients of all ages, synovial
sarcomas commonly occur in adolescents and
young adults, with a reported male predomin  -
ance.
3,4
Although  originally  believed  to  arise  from
the synovium because of their frequent peri-
articular location, synovial sarcomas can occur
virtually anywhere in the body, with less than
5% being microscopically continuous with the
synovium.
4 They are now thought to arise from
primitive undifferentiated mesenchymal cells.
5
While the majority of synovial sarcomas occur
in skeletal muscle and supporting connective
tissues of the extremities, most often in the
leg,
6 they have also been reported in a variety
of  other  anatomical  locations  including  the
head,  neck,  mediastinum,  heart,  esophagus,
pleura, small intestine, and lung.
5
We report here an extremely rare case of
synovial  sarcoma  arising  from  the  median
nerve. To our knowledge, this is the twelfth
reported case of intraneural synovial sarcoma,
and only the fourth arising from the median
nerve.
Case Report
A 66-year-old, right-hand dominant woman,
with no significant past medical history, pre-
sented  with  pain  in  her  right  hand  for  one
month. The pain was sharp, worse at night,
and localized to her thenar eminence. She also
complained  of  diminished  sensation  of  her
radial three digits, and recently she had been
dropping objects. She had noted a mass on the
volar aspect of her right wrist for the past 25
years, which had gradually diminished in size.
On examination, an approximately 2¥3 cm,
moderately  tender  mass  was  noted  on  the
medial-volar aspect of the patient’s right wrist.
Tinel’s sign was positive over the carpal tun-
nel,  and  atrophy  of  the  thenar  muscles  was
present. The neurovascular examination was
otherwise within normal limits.
Electrodiagnostic  tests,  including  elec-
tromyography and a nerve conduction study of
the median nerve, were within normal limits.
Magnetic  resonance  imaging  showed  a
2.7¥1.95¥1.35 cm, ovoid, lobular, heterogenous
mass arising from the median nerve and nerve
sheath. On T1-weighting, the mass was slight-
ly brighter than skeletal muscle with punctate
lower-signal foci. On T2-weighting, geographic
foci of intermediate intensity were seen cen-
trally with a brighter signal peripherally. The
radiologist’s impression, which was shared by
the surgeon, was of a probable neurofibroma or
schwannoma.  With  this  in  mind,  marginal
resection  of  the  mass  was  undertaken  with
preservation of nerve fascicles where possible.
The mass was found to be associated intimate-
ly with the nerve. Most of the nerve was seen to
be intact at the end of the procedure. 
Histopathology  showed  a  2¥0.2¥0.2  cm,
gray-tan,  firm  mass.  A  typical  spindle-cell 
morphology was seen with hematoxylin-and-
eosin  staining  (Figure  1).  Immunohistoche-
mically the tumor stained diffusely positive for
vimentin  and  cytokeratins  AE1/AE3,  CK7,
CK18, and CK19, as well as bcl-2. There was
also  patchy  positive  staining  for  EMA  and
CD99. Stains for smooth muscle actin, desmin,
CD31,  CD34,  and  S-100  were  negative.  The
histopathological  and  immunohistochemical
assessments are consistent with a diagnosis of
a  monophasic  intraneural  synovial  sarcoma.
Fluorescent  in  situ hybridization  resulted  in
30% of cells showing heterozygous rearrange-
ment of the SYT locus on 18q11.2; this type of
SYT  rearrangement  is  characteristic  of  syn-
ovial sarcoma (see Discussion). 
Given the diagnosis of the malignant neo-
plasm, a radical resection of the lesion with
reconstruction was performed six weeks later.
An  extensor  indicis  proprius  opponensplasty
was performed in order to return some thumb
function lost from the median nerve palsy. The
median nerve was identified inside the carpal
tunnel and followed proximally into the fore-
arm, and approximately 8 cm of it was removed
and sent for margin analysis. All frozen and
permanent sections taken from the tumor bed
were reported to be free of synovial sarcoma.
In  addition,  microsurgical  nerve  transfers
using the ulnar digital nerve of the ring finger,
the radial digital nerve of the little finger to the
index finger proper digital nerve, and the pal-
mar sensory nerve to the thumb, respectively,
were sutured with 9-0 nylon. At the six-month
follow-up,  the  patient  was  status  post-radio-
therapy, and had approximately 20% range of
motion  of  her  digits  owing  to  scarring  and
edema. She had no sensation in the reinnerv  -
ated digits. 
Discussion
Intraneural synovial sarcomas are extreme-
ly rare, with our case being one of only a hand-
ful  reported  in  the  literature.
7-16 Previously,
three intraneural synovial sarcomas have been
reported arising from the median nerve, along
with one apiece from the radial, common digit  -
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al,  posterior  tibialis,  peroneal,  and  facial
nerves and one from each of the S1 root, C7
root, and brachial plexus (Table 1).
Three separate histopathological patterns of
synovial  sarcoma  are  recognized.  The  most
commonly reported overall is the biphasic type,
consisting of distinct epithelial cells in gland-
like  arrangements  along  with  fibroblast-like
spindle  cell  components  in  varying  propor-
tions. Monophasic tumors, such as the one in
our  case,  morphologically  consist  of  spindle
cells only and were difficult to distinguish from
other soft tissue and nerve tumors before the
introduction of immunostaining for epithelial
membrane  antigen  (EMA),  vimentin,  S-100,
and cytokeratins CK7, CK19, and CD99.
4 The
epithelial components of monophasic synovial
sarcomas only become evident when stained
for EMA and cytokeratins, although these are
not  specific  for  synovial  sarcoma.  A  third
histopathological pattern of synovial sarcomas,
the poorly differentiated subtype, is also recog-
nized.
5 While poorly differentiated tumors are
associated with a worse prognosis, the prog-
nostic  value  of  monophasic  versus  biphasic
tumors is still debated.
11,17-19 Although biphasic
morphology is most frequently reported over-
all,  eight  of  the  twelve  reported  intraneural
synovial  sarcomas  have  had  monophasic
histopathology. Of those reported to arise from
the median nerve, three of the four have been
monophasic, with one biphasic. 
Cytogenetic  testing  is  the  most  definitive
way to establish the diagnosis of synovial sar-
coma.  A  stereotyped  gene  translocation
between  chromosomes  18  and  X  t(x;18)
(p11.2;q11.2) occurs in over 90% of synovial
sarcomas.
4 This leads to fusion of one of two
variants of the SSX gene with the SYT gene,
resulting in either the SYT/SSX1 or SYT/SSX2
chimeric fusion proteins.
4,5 Nearly all biphasic
tumors express SYT/SSX1, while monophasic
tumors  express  SYT/SSX1  in  approximately
half of the cases and SYT/SSX2 in the remain-
der.
18 Patients  with  SYT/SSX2  expressing
tumors have a significantly better prognosis
when  compared  to  those  with  SYT/SSX1
tumors  in  terms  of  rates  of  metastasis  and
overall survival.
18,20-22
Other factors reported to be associated with
poor prognosis include tumor size greater than
5 cm, areas of necrosis, bone or neurovascular
invasion, poor differentiation, and high mitot-
ic rate.
17,19,23 Although older age has also been
associated  with  a  poorer  prognosis,  more
recent studies have been unable to reproduce
this finding.
7
Adequate surgical margins, radiation ther  -
apy,  and  adjunct  chemotherapy  have  been
reported to correlate with better prognosis.
2,24
However, despite advances in treatment, mor-
tality rates of synovial sarcoma remain quite
high with five-year survival rates around 50-
60%.
2,3,25 Death  most  frequently  results  from
distant  metastases,  most  commonly  to  the
lung.
5 While improved local control with radical
surgical excision and irradiation has led to a
substantial decrease in local recurrence, rates
of distant metastatic disease remain high even
with systemic chemotherapy.
17
Synovial  sarcoma  is  an  aggressive  tumor
that can occur nearly anywhere in the body,
including within peripheral nerves as illustrat-
ed in our case. Although extremely rare, the
potential for a malignancy such as an intra-
neural synovial sarcoma was presented in the
differential diagnosis to this patient. This is
important  since  the  diagnosis  may  not  be
apparent until after pathological examination
of the surgical specimen, resulting in drastic
alterations to the original treatment strategy
and an altered impact on the patient. While the
presence  of  a  nerve  tumor  most  commonly
indicates a benign lesion, one must be cog-
nizant of the potential for a life-threatening
malignancy, and that the diagnosis will not be
final  until  a  pathological  examination  has
been completed.
Case Report
Table 1. Reported cases of intraneural synovial sarcoma.
Author  Age  Sex Nerve Histology EMA VIM KRT, CK S-100 protein CD99 Cytogenetics Surgery
(Year) (yrs)
Cugola and Pisa (1985)
14 16 F radial biphasic ++ + + - ER
Rinehart et al.(1989)
15 23 F median monophasic - ER
O'Connell et al.(1996)
7 16 F common digital biphasic ++ + - - ER
Tacconi et al.(1996)
12 44 F brachial plexus monophasic ++ + ± - TR
Spielmann et al.(1997)
11 43 M posterior tibialis monophasic ++ + - +SYT-SSX A
Chesser et al.(1999)
8 16 ND median biphasic ++ - TR
Zenmyo et al.(2001)
16 58 F S1 root monophasic ++ + + SYT-SSX1 TR
Lestou et al.(2002)
10 54 M peroneal monophasic ++ + + +SYT-SSX2 TR
Chu et al.(2004)
9 46 F facial biphasic ++ + - - SYT-SSX ER
11 F C7 root monophasic -+ - - +SYT-SSX TR
Uehara et al.(2008)
13 33 F median monophasic +± + + SYT-SSX1 TR
Current study 66 F median monophasic ++ + - + - TR
EMA, epithelial membrane antigen; VIM, vimectin; KRT, keratin; CK, cytokeratin; ER, extended resection; TR, total resection; A, amputation. Modified with permission from Uehara, et al. (2008).
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Figure 1. Hematoxylin-and-eosin staining
shows  atypical  spindle-cell  morphology
associated  with  intraneural  synovial  sar  -
coma at 200X (A) and 400X (B) magnifica-
tions. (C) Immunohistochemical staining
was diffusely positive for cytokeratins. 
A
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